BASF Pharma Ingredients and Services - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

BASF Pharma Ingredients and Services

The innovative PeroXeal™ packaging concept sets new standards in the market by protecting BASF’s PVP-based excipients (marketed under the trade name Kollidon®) from environmental influences such as atmospheric oxygen. Thanks to the new packaging, which applies established barrier technologies to the needs of the pharmaceutical ingredient market, Kollidon’s peroxide content can be reduced to a level comparable with that of naturally-based raw materials. This significantly increases stability and ensures consistent performance – and makes Kollidon a viable alternative to cellulose when working with oxygen-sensitive ingredients.

As the packaging extends Kollidon’s retest period to up to four years, customers benefit from increased flexibility in the planning, handling and shipping of goods. Additionally, the longer shelf life helps mitigate risk and provides a greater safety margin.

The PeroXeal packaging concept is a combination of multiple film layers complemented by inert gas flushing and heat sealing. The foil comprises three distinct functional layers, each specifically designed to shield the product from environmental influences. The transparent inner lining is compatible with non-invasive NIR testing – so packaging remains airtight until the product is put to use.

A large number of Kollidon products are already available in PeroXeal packaging – at no additional cost to the customer.

Contact details

www.kollidon.com/kollidon/PeroXealconcept.aspx?
pharma-ingredients@basf.com

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
FindPharma Custom Search

Click here